Tag: management

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

Uniform leader Image Solutions streamlines color and materials management and prepares for global vendor integration CAMPBELL, Calif., Aug. 12, 2025 /PRNewswire/ -- Centric Software® is...

IRVING, Texas, Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results...

PORTLAND, Ore., Aug. 12, 2025 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW), a leading provider of innovative video and display processing solutions, today announced financial results...

TORRANCE, Calif., Aug. 12, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ: PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle...

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- The Bank of New York Mellon Corporation ("BNY") (NYSE: BK), a global financial services company, will report financial results...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, Aug. 12, 2025 /CNW/ - Applied Graphite Technologies...

MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management firm, for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. 

Zurich, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- FGLFIN Investments, a leader in cryptocurrency trading and asset management, has been named to the Global Top 10 Investment Firms list for 2025. The recognition follows a strong third quarter in which the company delivered exceptional results across client portfolios, increased assets under management, and expanded its global market presence.